novel

Well-chosen quantity: only contains 989 bioactive compounds after careful selection

A unique collection of 2975 approved drugs for high throughput screening (HTS) and high content screening (HCS);

3400 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 718 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

A unique collection of 3163 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 500 natural alkaloids can be used for high throughput and high content screening;

A unique collection of 1812 natural products with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS);

A unique collection of 5550 approved and clinical drugs for high throughput screening (HTS) and high content screening (HCS);

For your convenience, there are Diversity Sets of 5,000, 10,000, 15,000, and 20,000 compounds with no structure overlap.

The unparalleled chemical diversity of natural products makes them an ideal choice for screening active small molecules. Natural products is always a significant source in drug discovery. According to authoritative statistics, 79 out of 99 small molecule anticancer drugs have been successfully developed based on natural products since 1981. Natural products have demonstrated successful modulation of isolated but crucial targets, especially in antimicrobial targets and protein interactions. Many researchers consider natural products and their derivatives as unique tools for studying and manipulating protein function. The Drug-like Natural Compound Library comprises 522 novel molecules, serving as a complement to the L6000 Natural Product Library. This library enhances the probability of successful drug screening, making it an excellent tool for lead compound discovery.

A unique collection of 680 EMA-approved drugs for high throughput screening (HTS) and high content screening (HCS);

A collection of 230 small-molecule compounds approved by the U.S. FDA for veterinary use, suitable for high-throughput screening (HTS) and high-content screening (HCS)

A unique collection of 1133 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents;

A unique collection of 523 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening;

A unique collection of 941 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer;

A collection of 27752 bioactive compounds for high-throughput screening, high-content screening, cell induction and target identification.

Large quantity: contains 193,000 natural product derivatives and the number is continuously updating;

A unique collection of 170 sodium channel blockers and agonists for high throughput and high content screening;

A unique collection of 210 ubiquitination related small chemicals can be used for high throughput and high content screening;